Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mim8 in children with hemophilia A with or without inhibitors
CTR20230723Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Started Mar 2023; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20230723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230723.